eMAX Health

What They Do

eMAX Health Systems (legal entity: eMAX Health Systems, LLC) operates three integrated service lines built around what they call an “Evidence, Access, and Reimbursement” platform — the key differentiator being that all three legs feed each other in a continuous data loop rather than operating as siloed businesses.

Market Access Research & Strategy: Custom primary research via MAVA (Market Access Vision Advisers), a digital customer engagement platform with a panel of 1,100+ validated payer and provider advisers. MAVA supports real-time group chat, rapid polls, surveys, and AI-assisted moderation. Embedded modules include Elasticity (price simulation using validated product analogs) and Contracting ROI (rebate tradeoff modeling, market share simulation). The account management arm deploys 3-6 national account executives per client in a shared-resource model for companies that can’t afford dedicated national account teams (eMAX Health).

Evidence Development (HEOR/RWE): Anchored by EMRClaims+, a proprietary linked EMR + claims database containing 20M+ electronic medical records across 9 states plus 2M+ commercially insured lives, updated within 30 days of extract. eMAX uses this for patient journey mapping, predictive risk modeling, retrospective data studies, budget impact/cost-effectiveness modeling, and reimbursement dossiers. They have published in peer-reviewed journals across asthma, migraine (fremanezumab), and VTE (EMRClaims+ PDF).

Patient Access & Hub Services: Operated under the “eMAX Health Patient Services” brand. Core capabilities include automated benefit investigation/verification, medical benefit ePA, appeals management, copay assistance (medical benefit), specialty pharmacy referral, PAP administration, patient/prescriber web portals, FRM territory dashboards, telehealth monitoring, and home health coordination. The HealthPACER case management platform supports 350+ healthcare institutions and 10,000+ prescribers, and can be out-licensed for hybrid/insourced models (eMAX Health).

How the three connect: Hub access data identifies payer barriers -> account managers deploy targeted intervention -> MAVA research refines payer messaging -> EMRClaims+ RWE supports contracting dossiers -> ResponseRx (a point-of-care outcomes assessment platform) enables outcomes-based contracts on actual clinical response, driving re-authorization eligibility (eMAX Health).

Competitive Positioning

eMAX sits at Tier 3 / niche integrated provider — too small (30-50 employees, ~$5-6M estimated revenue) for high-volume transactional hub programs, but occupying a unique position that no pure-play competitor replicates: the integration of payer research, HEOR/RWE, and hub operations under one roof.

For hub services: Competes with CareMetx, AssistRx, Lash Group, Eversana on hub capabilities but at much smaller scale. Differentiated by out-licensing flexibility (HealthPACER for hybrid models) and the research feedback loop.

For market access research: Competes with MMIT, Lumanity, PRECISIONadvisors, Certara on advisory capabilities but differentiated by having its own hub data to inform payer strategy.

The company was cited among five recommended hub platforms by a CM CoPilot roundup alongside Asembia, CareMetx, EnvoyHealth, and CoPilot Provider Support Services (blog.cmcopilot.com).

Recent Developments (2024-2026)

• January 2025: PE investment by Fengate Private Equity (Toronto; managing on behalf of LiUNA Pension Fund of Central and Eastern Canada). Terms undisclosed. Structured as a platform investment / growth equity. Julian Casciano and management team remain significant co-investors (GlobeNewswire).
• April 2024: Eric Bishea hired as President, MAVA Business Unit (formerly GlobalData), signaling MAVA’s elevation to a formal business unit.
• June 2025: Essy Mozaffari (PharmD, MPH, MBA; ex-Gilead, Pfizer, Sanofi) hired as SVP, Head of Real-World Evidence to drive global RWE expansion and digital MSL platform launch (GlobeNewswire).
• 2025-2026: Active content marketing focused on IRA (Inflation Reduction Act) pricing implications — strategic positioning as go-to advisory partner for drug pricing reform navigation. Global EMRClaims+ expansion initiative underway.
• February 2026: CEO Julian Casciano featured on the Molecule to Market podcast, discussing growth journey and Fengate partnership (Molecule to Market).

Client Types & Therapeutic Focus

Primary target: Small to mid-size biopharma and biotech companies that cannot cost-effectively build separate national account management, HEOR, and hub functions. The Fengate press release also references “the largest global pharmaceutical and biotechnology companies” as clients. Account management operates a shared-resource model (3-6 reps per client) (Fengate).

Therapeutic areas: Documented in publications and programs — asthma, COPD, immunology (biologics), migraine, VTE/vascular, oncology, cell and gene therapy. Peer-reviewed publications in allergy/asthma journals, headache/pain, and vascular therapeutics.

Scale: 65+ programs, 10,000+ prescribers, 350+ institutions using HealthPACER.

Technology

Platform	Description
MAVA	Always-on digital payer/provider engagement platform; 1,100+ validated advisers; AI-assisted moderation; Pulse Reports
Elasticity	Price simulation module within MAVA; validated product analogs
Contracting ROI	Rebate tradeoff and market share modeling within MAVA
EMRClaims+	Proprietary linked EMR (20M+ records, 9 states) + claims (2M+ lives) database; updated within 30 days
HealthPACER	Patient services case management; ePA, BV, copay, FRM dashboards; out-licensable for hybrid/insourced models
ResponseRx	Point-of-care outcomes assessment platform enabling outcomes-based contracting on actual clinical response
BASE	Internal analytics dashboard for account management
Digital MSL Platform	New launch (details limited) for medical science liaison engagement

Certified SAS data services provider. HIPAA-compliant platforms (eMAX Health technology).

Financial Context

Metric	Detail
Revenue estimate	~$5-6M annually (RocketReach, Growjo — unverified)
Employees	30-50 (LinkedIn: 11-50; Growjo: 30; 43% YoY growth reported)
PE investor	Fengate Private Equity (on behalf of LiUNA Pension Fund); investment amount undisclosed
Ownership	Fengate (significant); Julian Casciano and management (co-investors)
Revenue per employee	~$201K (Growjo estimate)
Founded	2004 by Julian Casciano (CEO)
Additional offices	White Plains, NY; Beachwood, OH; Toronto, ON

Founder Julian Casciano holds a Cornell B.S. (economics/life sciences), was formerly CMO at Biovest International, founded Analytica International, and served as Senior Manager at KPMG Peat Marwick (eMAX Health).

Analyst Observations

1. The research-to-hub feedback loop is genuinely differentiated and difficult to replicate. Most hub vendors sell patient access services; most market access advisory firms sell research. eMAX’s integration — where hub access data directly identifies payer barriers that account managers then address, with RWE supporting contracting — creates a flywheel that pure-play competitors in either category can’t easily match. At scale, this is extremely valuable; the constraint is that eMAX hasn’t yet achieved that scale.

2. ResponseRx is a sleeper asset. Outcomes-based contracting on actual clinical response (not proxy metrics like claims or adherence) is a capability that pharma manufacturers increasingly need as payer demands for value-based contracts grow. Very few hub providers offer this. If eMAX can scale ResponseRx alongside the IRA-driven demand for value-based pricing, this could be a significant growth vector.

3. The Fengate PE investment signals a platform build. Fengate’s “platform investment” language and the immediate senior hires (Mozaffari for RWE, Bishea for MAVA) suggest add-on acquisitions are expected. At ~$5-6M revenue with a unique research-hub integration model, eMAX could become an acquirer in the fragmented market access advisory space or itself become an acquisition target for a larger hub vendor seeking upstream capabilities. The IRA positioning (heavy content marketing on drug pricing reform) is a timely bet.

Sources

• eMAX Health Website
• eMAX Health Market Access
• eMAX Health Patient Access
• eMAX Health Programs
• eMAX Health Technology
• EMRClaims+ PDF
• Fengate partnership PR
• Essy Mozaffari hire PR
• Molecule to Market podcast
• CM CoPilot hub roundup
• Wave 3 research: wiki/raw/research/wave3-batch-a-hub-vendors.md